Waters Corporation: Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization NEWS SUMMARY: Collaboration intended to bring speed and simplicity to bio-characterization workflows Automated workflows to cut the time and effort required to monitor critical quality attributes of biotherapeutics in regulated laboratories Waters and Genovis share goal of advancing the science behind the analysis of glycoproteins and protein therapeutics Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).